Role Of Precision Medicine In Driving The RNA Sequencing Market Driving Market Acceleration in the Ribonucleic Acid (RNA) Sequencing Industry, 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Ribonucleic Acid (RNA) Sequencing Market Size By 2025?
The market size for ribonucleic acid (RNA) sequencing has seen a significant growth spurt in recent years, with a projected growth from $3.25 billion in 2024 to $3.98 billion in 2025, representing a compound annual growth rate (CAGR) of 22.7%. Several factors contributed to this growth during the historic period, including an upsurge in drug development activities, an increased occurrence of genetic disorders and other target diseases, the expanded use of miniaturized portable instruments and biomarker profiling. Additionally, a surge in demand for personalized medicine and a rise in cancer patients also drove the growth.

How Big Is the Ribonucleic Acid (RNA) Sequencing Market Size Expected to Grow by 2029?
Expectations are high for the RNA sequencing market, with a forecast predicting substantial expansion in the near future. By 2029, projections place the market's value at $8.91 billion, a figure driven by a compound annual growth rate (CAGR) of 22.3%. A variety of factors are set to fuel this growth over the forecast period including increased need for swift and precise disease diagnosis, widespread acceptance of real-time polymerase chain reaction, a rising demand for immediate on-site diagnostic tests, a proliferation of infectious disease outbreaks, and a surge in demand for companion diagnostics. Key trends ushering the forecast period include disease detection and monitoring, drug exploration, target checking, the identification of biomarkers, DNA sequencing technologies, advances in diagnostic testing, next-generation sequencing (NGS), microfluidics, lab-on-a-chip platforms and the development of novel molecular diagnostic solutions.

View the full report here:
https://www.thebusinessresearchcompany.com/report/ribonucleic-acid-rna-sequencing-global-market-report

Which Key Market Drivers Powering Ribonucleic Acid (RNA) Sequencing Market Expansion and Growth?
The progression of the ribonucleic acid (RNA) sequencing market is predicted to be stimulated by an intensified concentration on precision medicine. Precision medicine refers to a groundbreaking approach to prevention and treatment in the medical field that takes into account the unique genetic variations, personal environment, and lifestyle of each individual. It opens up the possibility for more effective therapies, progressive advancements in genomics, escalating disease intricacy, and authoritative support. RNA sequencing methodologies are harnessed to identify the sequence and evaluate the expression magnitude of RNA molecules in a given sample. This allows for an extensive assessment of transcriptomes and a deeper understanding of gene expression trends, alternate splicing episodes, and RNA modifications. Take the Personalized Medicine Coalition, a non-profit organization based in the US, for example. In February 2024, they reported that 16 new personalized therapies for patients suffering from rare diseases were approved by the FDA in 2023, a substantial increase from the six approved in 2022. Consequently, this amplified emphasis on precision medicine is propelling the growth of the ribonucleic acid (RNA) sequencing market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15665&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Ribonucleic Acid (RNA) Sequencing Market?
Major corporations functioning in the ribonucleic acid (RNA) sequencing market are emphasizing on RNA next-generation sequencing assay in an attempt to enhance patient treatment through the use of evidence-based insights and precision medicine. RNA next-generation sequencing assay is a progressive exome sequencing platform that uses cutting-edge genomic sequencing technologies in patient's complete exome analysis. Tempus, a US-based firm specializing in precision medicine technology, launched its standalone RNA next-generation sequencing assay, Tempus xR, in June 2023. This revolutionary assay, tailored for solid tumors, enables a thorough study of the entire transcriptome, underscoring clinically relevant fusions in over 100 targeted genes and altered MET Exon 14 and EGFRvIII splicing. The product is aimed at physicians interested in RNA fusions or altered splicing as well as providers, researchers, and biopharmaceutical firms seeking in-depth RNA sequencing analysis of their existing samples.

What Are the Emerging Segments in the Ribonucleic Acid (RNA) Sequencing Market?
The ribonucleic acid (RNA) sequencing market covered in this report is segmented -

1) By Product Type: Instruments, Reagents And Kits, Software
2) By Technology: Single Molecule Based Sequencing, Sequence By Synthesis Technology, Nanopore Sequencing Technology, Ion Torrent Semiconductor Sequencing
3) By Applications: Diagnostics, Drug Discovery, Translational Medicine, Other Applications
4) By End User: Research And Academia, Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Other End Users

Subsegments:
1) By Instruments: Next-Generation Sequencers, Microarray Instruments, Single-Cell Rna Sequencing Instruments
2) By Reagents And Kits: Rna Extraction Kits, Rna Sequencing Kits, Library Preparation Kits
3) By Software: Data Analysis Software, Data Management Software, Bioinformatics Software

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15665&type=smp

Who Are the Global Leaders in the Ribonucleic Acid (RNA) Sequencing Market?
Major companies operating in the ribonucleic acid (RNA) sequencing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Becton, Dickinson and Company, GE HealthCare Technologies Inc., Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., bioMérieux SA, Beckman Coulter Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Tecan Genomics Inc., Natera Inc., Myriad Genetics Inc., BGI Genomics Co Ltd., Takara Bio Inc., Cepheid, NeoGenomics Laboratories Inc., Abcam Limited, Oxford Nanopore Technologies plc, Pacific Biosciences of California Inc., Macrogen Inc., Standard BioTools Inc., Ambry Genetics Corporation, Biocartis SA, CD Genomics

Which are the Top Profitable Regional Markets for the Ribonucleic Acid (RNA) Sequencing Industry?
North America was the largest region in the ribonucleic acid (RNA) sequencing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid (RNA) sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15665

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.